Increase Fertility Age with Traditional Cancer Therapy!

A conventional cancer drug can reverse the aging of women’s ovaries, which can lead to increased childbearing years and delayed menopause.

Rapamycin, also known as sirolimus, is a once-weekly pill that suppresses the immune system and is used to treat cancer and prevent organ rejection after a heart transplant or heart stent surgery. It has been identified as an anti-aging drug or a drug that can delay or reverse aging.

In recent years, it has been flagged as a potential life-extending drug after promising studies in mice showed that it could increase overall lifespan.

For example, a 2021 review in the journal GeroScience examined the effects of rapamycin in mice. The researchers found that rapamycin increased the lifespan of male and female mice by more than 90 percent.

“This drug affects the basic biology of aging and thus prolongs health and lifespan in animal models,” said Dr. Yusin Sukh, professor of genetics at Columbia University. “In the long term, it may help women live healthier and longer lives.”

Su and Columbia University researcher Dr. Ziff Williams are leading a study called Evidence-Based Benefits of Rapamycin for Reproductive Aging (VIBRANT) to test whether rapamycin can have the same longevity properties on a woman’s ovaries.

The study participants included women who tried and failed to conceive a child naturally or through procedures such as IVF.

“We are interested in reproductive aging in women, especially ovarian aging, because the ovaries are the first aging organ in the human body,” Suh said.

She explained that the aging process is amazing. By the time a woman is in her 30s, her ovaries are already shrinking rapidly. This aging is eventually exacerbated by menopause, which begins at an average age of 51 in the United States.

“We have very little information about why the ovaries age so quickly compared to other organs,” Suh said.

The goal of the VIBRANT study is to slow down this process.

“Rapamycin is considered one of the gold standards for anti-aging drugs, so it was clear to us that rapamycin can act on the ovaries and thus slow down ovarian aging, including menopause and age-related decline in fertility,” Suh said. .

While the study is just getting started, if successful, it could be a game-changer for women in the US who later have children and prioritize their careers.

Rapamycin can also delay menopause. Although most women reach menopause at age 50, only one in 20 women reaches this point by age 45.

This process is preceded by several years of amenorrhea, which lasts an average of two to eight years, followed by up to 14 years of amenorrhea.

Menopause comes with a host of uncomfortable symptoms, ranging from unpleasant to debilitating.

These include changes in the menstrual cycle, hot flashes, night sweats, weight gain, decreased sex drive, depression, heart attack, and stroke.

Women who go through menopause at an early age are also at greater risk of health problems such as heart disease, osteoporosis, and even dementia.

One study found, for example, that women who experienced menopause-related hot flashes and bouts of depression were more likely to have cognitive impairment associated with dementia.

And unlike egg freezing, which produces more eggs that are stored outside the body for later, the drug works to keep those eggs inside the body.

This will allow the ovaries to function like younger, healthier ovaries. Healthy ovaries control the release of eggs with an enzyme called mTOR, or the mammalian target of rapamycin.

Regulation of egg release can safely slow down reproductive aging and prolong a woman’s fertile period. This means they can have children later in life and delay the onset of menopause.

However, too much mTOR can completely stop ovulation.

At the beginning and end of the three-month period, researchers will measure each woman’s antibody levels. This is the main indicator of reproductive health. It corresponds to the number of eggs that each woman holds and is a sign of fertility.

Su said it’s too early to tell if this is the key to slowing down ovarian aging.

Source: Daily Mail